Results 31 to 40 of about 17,488 (290)

Subcutaneous Biopharmaceutics: Building tools for a flexible future

British Journal of Pharmacy, 2023
The major biopharmaceutics challenge faced during the development of subcutaneous (SC) drug products is the limited understanding of the physiological factors and the combination product attributes that can impact absorption rate/extent and drug product ...
Kate Louise Harris , J Matthew Wood , Laura Garcia Gonzalez, Simon Todd, Iain Grant   +4 more
doaj   +1 more source

Metal-organic frameworks for advanced drug delivery

Acta Pharmaceutica Sinica B, 2021
Metal-organic frameworks (MOFs), comprised of organic ligands and metal ions/metal clusters via coordinative bonds are highly porous, crystalline materials.
Siyu He, Li Wu, Xue Li, Hongyu Sun, Ting Xiong, Jie Liu, Chengxi Huang, Huipeng Xu, Huimin Sun, Weidong Chen, Ruxandra Gref, Jiwen Zhang   +11 more
doaj   +1 more source

Synthesis of Gold Nanoparticles Using Leaf Extract of Ziziphus zizyphus and their Antimicrobial Activity

Nanomaterials, 2018
(1) Background: There is a growing need for the development of new methods for the synthesis of nanoparticles. The interest in such particles has raised concerns about the environmental safety of their production methods; (2) Objectives: The current ...
Alaa A. A. Aljabali, Yazan Akkam, Mazhar Salim Al Zoubi, Khalid M. Al-Batayneh, Bahaa Al-Trad, Osama Abo Alrob, Alaaldin M. Alkilany, Mourad Benamara, David J. Evans   +8 more
doaj   +1 more source

A DNA Vaccine Encoding the Full-Length Spike Protein of Beta Variant (B.1.351) Elicited Broader Cross-Reactive Immune Responses against Other SARS-CoV-2 Variants

Vaccines, 2023
The SARS-CoV-2 pandemic remains an ongoing threat to global health with emerging variants, especially the Omicron variant and its sub-lineages. Although large-scale vaccination worldwide has delivered outstanding achievements for COVID-19 prevention, a ...
Gan Zhao, Zhiyu Zhang, Yuan Ding, Jiawang Hou, Ying Liu, Mengying Zhang, Cheng Sui, Limei Wang, Xin Xu, Xiaoming Gao, Zhihua Kou   +10 more
doaj   +1 more source

A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB

Vaccines, 2023
Waves of breakthrough infections by SARS-CoV-2 Omicron subvariants currently pose a global challenge to the control of the COVID-19 pandemic. We previously reported a pVAX1-based DNA vaccine candidate, pAD1002, that encodes a receptor-binding domain (RBD)
Yuan Ding, Feng Fan, Xin Xu, Gan Zhao, Xin Zhang, Huiyun Zhao, Limei Wang, Bin Wang, Xiao-Ming Gao   +8 more
doaj   +1 more source

BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide

Pharmaceutics, 2020
Biopharmaceutical classification system (BCS) class IV drugs (low-solubility low-permeability) are generally poor drug candidates, yet, ~5% of oral drugs on the market belong to this class.
Milica Markovic, Moran Zur, Inna Ragatsky, Sandra Cvijić, Arik Dahan   +4 more
doaj   +1 more source

Biopharmaceutical benchmarks 2022

Nature Biotechnology, 2022
Monoclonal antibodies as a group continue to lead biopharmaceuticals in numbers of approvals and sales, although COVID-19 vaccines shot to the top of the list of highest-grossing individual products.
Walsh, Gary, Walsh, Eithne
openaire   +2 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Immunogenicity of biopharmaceuticals [PDF]

Nephrology Dialysis Transplantation, 2006
The availability of biopharmaceuticals has been increasing over the past decade and as their patents expire, the emergence of biosimilar agents approaches. The primary issue of concern for the safety of these agents is the potential for immunogenicity.
Michele, Kessler, David, Goldsmith, Huub, Schellekens   +2 more
openaire   +2 more sources

Oral Dosed Organo‐Silica Nanoparticles Restore Glucose Homeostasis and β‐Cell Function in Diabetes Rats

Advanced Functional Materials, EarlyView.
An oral nanoplatform, MOP@T@D, which can maintain glucose homeostasis and restore islet β cells in diabetic rats is developed. It achieves efficient intestinal absorption and liver‐targeted delivery. The nanoparticle disintegrates only in response to hyperglycemia to release insulin on demand and provides antioxidant protection through selenoprotein ...
Chenxiao Chu, Mingli Wei, Che Bian, Xiaoshuang Bi, Yaxin Deng, Peifu Xiao, Jiansong Zhao, Yuying Wang, Haibing He, Jingxin Gou, Tian Yin, Xing Tang, Li Yang, Hongbo Zhang, Yu Zhang   +14 more
wiley   +1 more source